- 30 мая
IPHARMA has participated in Iran Health International Exhibition 2022
Last week, IPHARMA team has been to Teheran to participate in Iran Health International Exhibition 2022, the biggest medical,...
- 31 янв. 2021 г.
IPHARMA obtained an approval to conduct the clinical trial of a drug against COVID-19
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II clinical trial of the drug CKD-506....
- 27 янв. 2021 г.
IPHARMA – the partner of Pharma's cool 2021
On March 2-5, 2021, the 7th educational program in the field of pharmaceuticals and biotechnology "Pharma's cool" will take place. For...
- 3 дек. 2020 г.
IPHARMA was authorized to conduct a Phase IIa clinical trial
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase IIa clinical trial of the drug...
- 29 нояб. 2020 г.
IPHARMA was authorized to conduct 2 clinical trials
On November 27, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase I clinical trial of the...
- 27 окт. 2020 г.
IPHARMA was authorized to conduct a Phase III clinical trial
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase III clinical trial of the drug АВ5080....
- 31 авг. 2020 г.
IPHARMA obtained an approval to conduct the clinical trial of a drug against COVID-19
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II clinical trial of the drug CKD-314....
- 11 авг. 2020 г.
The most frequently asked questions about candidate vaccines against SARS-CoV-2
Comments of Natalia Vostokova, PhD, IPHARMA Chief Operating Officer, on the development of vaccines against COVID-19 from Anna Remish's...
- 6 авг. 2020 г.
IPHARMA obtained an approval to conduct the clinical trial of a drug for post-Covid-19 rehabilitatio
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II clinical trial of the drug Treamid....
- 16 июл. 2020 г.
IPHARMA obtained an approval to conduct the clinical trial on COVID-19
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II/III clinical trial of the drug...